リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets

Akiyama, Masashi 名古屋大学

2022.01

概要

Pustular psoriasis is a chronic inflammatory skin disease characterized by erythematous plaques with sterile pustules. It includes the distinct clinical entities generalized pustular psoriasis (GPP), acrodermatitis continua of Hallopeau (ACH) and palmoplantar pustular psoriasis (PPPP). Recently clarified pathomechanisms of pustular psoriasis indicate that hyperactivation of the skin innate immunity, including of the IL-1/IL-36 axis, plays an important role in the pathogenesis of pustular psoriasis. Autoinflammatory keratinization disease (AiKD) is the umbrella clinical entity for inflammatory keratinization disorders with genetic autoinflammatory pathomechanisms, and pustular psoriasis is a representative AiKD. To date, mutations/variants in five genes—IL36RN, CARD14, AP1S3, MPO and SERPINA3—have been reported to be genetic causative or predisposing factors for pustular psoriasis. The pathogenic mechanisms induced by the mutations/variants in these genes are all closely related to the excessive activation of skin innate immunity and autoinflammation. A number of biologics (e.g., tumor necrosis factor inhibitors, IL-17/IL-17 receptor inhibitors and IL-23 inhibitors) and granulocyte and monocyte adsorption apheresis are used to treat pustular psoriasis. Recently, based on novel information on the pathomechanisms of pustular psoriasis, which are mainly associated with autoinflammation, inhibitors of several pathogenic pathways, including of the IL-1, IL-36, IL-8 and granulocyte colony-stimulating factor signaling pathways, have been studied as emerging treatments.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

[1] S. Marrakchi, P. Guigue, B.R. Renshaw, A. Puel, X.Y. Pei, S. Fraitag, et al., Interleukin-36- receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365 (2011) 620-628.

[2] K. Sugiura, M. Muto, M. Akiyama, CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J. Invest. Dermatol. 134 (2014) 1755-1757.

[3] T. Takeichi, A. Kobayashi, E. Ogawa, Y. Okuno, S. Kataoka, M. Kono, et al., Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation. Br. J. Dermatol. 177 (2017) e133-e135.

[4] N. Setta-Kaffetzi, M.A. Simpson, A.A. Navarini, V.M. Patel, H.C. Lu, M.H. Allen, et al., AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am. J. Hum. Genet. 94 (2014) 790-797.

[5] S. Haskamp, H. Bruns, M. Hahn, M. Hoffmann, A. Gregor, S. Löhr, et al., Myeloperoxidase modulates inflammation in generalized pustular psoriasis and additional rare pustular skin diseases. Am. J. Hum. Genet. 107 (2020) 527-538.

[6] S. Frey, H. Sticht, D. Wilsmann-Theis, A. Gerschütz, K. Wolf, S. Löhr, et al., Rare loss-of- function mutation in SERPINA3 in generalized pustular psoriasis. J. Invest. Dermatol. 140 (2020) 1451-1455.e13.

[7] M. Akiyama, T. Takeichi, J.A. McGrath, K. Sugiura, Autoinflammatory keratinization diseases. J. Allergy Clin. Immunol. 140 (2017) 1545-1547.

[8] M. Akiyama, T. Takeichi, J.A. McGrath, K. Sugiura, Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin. J. Dermatol. Sci. 90 (2018) 105-111.

[9] K. Sugiura, N. Oiso, S. Iinuma, H. Matsuda, M. Minami-Hori, A. Ishida-Yamamoto, et al., IL36RN mutations underlie impetigo herpetiformis. J. Invest. Dermatol. 134 (2014) 2472-2474.

[10] M. Yoshikawa, D. Rokunohe, A. Kimura, M. Takahashi, A. Korekawa, K. Nakajima, et al., Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: A case report and review of published cases. J. Dermatol. 48 (2021) 699-702.

[11] M. Murakami, T. Terui, Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism. J. Dermatol Sci. 98 (2020) 13-19.

[12] M. Akiyama, Autoinflammatory keratinization diseases (AiKDs): Expansion of disorders to be included. Front. Immunol. 11 (2020) 280.

[13] A. Onoufriadis, M.A. Simpson, A.E. Pink, P. Di Meglio, C.H. Smith, V. Pullabhatla, et al., Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 89 (2011) 432-437.

[14] S. Twelves, A. Mostafa, N. Dand, E. Burri, K. Farkas, R. Wilson, et al., Clinical and genetic differences between pustular psoriasis subtypes. J. Allergy Clin. Immunol. 143 (2019) 1021- 1026.

[15] A. Johnston, X. Xing, L. Wolterink, D.H. Barnes, Z. Yin, L. Reingold, IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 140 (2017) 109- 120.

[16] R. Mössner, D. Wilsmann-Theis, V. Oji, P. Gkogkolou, S. Löhr, P. Schulz, et al., The genetic basis for most patients with pustular skin disease remains elusive. Br. J. Dermatol. 178 (2018) 740-748.

[17] K. Sugiura, A. Takemoto, M. Yamaguchi, H. Takahashi, Y. Shoda, T. Mitsuma, et al., The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J. Invest. Dermatol. 133 (2013) 2514-2521.

[18] T. Takeichi, Y. Togawa, Y. Okuno, R. Taniguchi, M. Kono, H. Matsue, et al., A newly revealed IL36RN mutation in sibling cases complements our IL36RN mutation statistics for generalized pustular psoriasis. J. Dermatol. Sci. 85 (2017) 58-60.

[19] M. Akiyama, Early-onset generalized pustular psoriasis is representative of autoinflammatory keratinization diseases. J. Allergy Clin. Immunol. 143 (2019) 809-810.

[20] S. Hussain, D.M. Berki, S.E. Choon, A.D. Burden, M.H. Allen, J.I. Arostegui, et al., IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J. Allergy Clin. Immunol. 135 (2015) 1067-1070 e9.

[21] A. Adachi, M. Komine, T. Hirano, H. Tsuda, M. Karakawa, S. Murata, et al., Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab. J. Dermatol. 43 (2016) 1439-1440.

[22] C.T. Jordan, L. Cao, E.D. Roberson, K.C. Pierson, C.F. Yang, C.E. Joyce, et al., PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 90 (2012) 784-795.

[23] C.T. Jordan, L. Cao, E.D. Roberson, S. Duan, C.A. Helms, R.P. Nair, et al., Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am. J. Hum. Genet. 90 (2012) 796-808.

[24] D. Fuchs-Telem, O. Sarig, M.A. van Steensel, O. Isakov, S. Israeli, J. Nousbeck, et al., Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am. J. Hum. Genet. 91 (2012) 163-170.

[25] T. Takeichi, K. Sugiura, T. Nomura, T. Sakamoto, Y. Ogawa, N. Oiso, et al., Pityriasis rubra pilaris type V as an autoinflammatory disease by CARD14 mutations. JAMA Dermatol. 153 (2017) 66-70.

[26] S.K. Mahil, S. Twelves, K. Farkas, N. Setta-Kaffetzi, A.D. Burden, J.E. Gach, et al., AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J. Invest. Dermatol. 136 (2016) 2251-2259.

[27] M. Vergnano, M. Mockenhaupt, N. Benzian-Olsson, M. Paulmann, K. Grys, S.K. Mahil, et al., Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease. Am. J. Hum. Genet. 107 (2020) 539-543.

[28] S. Haskamp, J.S. Horowitz, V. Oji, S. Philipp, M. Sticherling, K. Schäkel, et al., Genetic analysis of mpo variants in four psoriasis subtypes in patients from Germany. J. Invest. Dermatol. 141 (2021) 2079-2083.

[29] T. Takeichi, M. Akiyama, Generalized pustular psoriasis: Clinical management and update on autoinflammatory aspects. Am. J. Clin. Dermatol. 21 (2020) 227-236.

[30] L.A. Falto-Aizpurua, R.F. Martin-Garcia, O.Y. Carrasquillo, O.W. Nevares-Pomales, X. Sánchez-Flores, D. Lorenzo-Rios, Biological therapy for pustular psoriasis: a systematic review. Int. J. Dermatol. 59 (2020) 284-296.

[31] T. Kanekura, Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders. J. Dermatol. 45 (2018) 943-950.

[32] S. Ikeda, H. Takahashi, Y. Suga, H. Eto, T. Etoh, K. Okuma, et al., Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. J. Am. Acad. Dermatol. 68 (2013) 609- 617.

[33] K. Sugiura, K. Haruna, Y. Suga, M. Akiyama, Generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis. J. Eur. Acad. Dermatol. Venereol. 28 (2014) 1835-1836.

[34] Y. Mizutani, K. Fujii, M. Kawamura, M. Inoue, Y.H. Mizutani, K. Matsuyama, et al., Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis. J. Dermatol. 47 (2020) 1326-1329.

[35] K. Fujii, T. Takahashi, K. Matsuyama, A. Fujii, Y. Mizutani, H. Ohnishi, et al., Impetigo herpetiformis with a CARD14 Thr79Ile variant successfully treated with granulocyte and monocyte adsorption apheresis. J. Dermatol. 47 (2020) e84-e85.

[36] A. Arimura, K. Fujii, A. Ibusuki, M. Hatanaka, M. Sakanoue, Y. Higashi, et al., Granulocyte and monocyte adsorption apheresis for palmoplantar pustulosiswith extra- palmoplantar lesions and pustulotic arthro-osteitis. J. Dermatol. 45 (2018) e167-e168.

[37] S. Cro, V.R. Cornelius, A.E. Pink, R. Wilson, A. Pushpa-Rajah, P. Patel, et al., Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two staged, adaptive placebo controlled trial (APRICOT). Br. J. Dermatol. (in press) 2021 Aug 19; Online ahead of print.

[38] B. Mansouri, L. Richards, A. Menter, Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br. J. Dermatol. 173 (2015) 239-241.

[39] P. Skendros, C. Papagoras, I. Lefaki, A. Giatromanolaki, I. Kotsianidis, M. Speletas, et al., Successful response in a case of severe pustular psoriasis after interleukin-1b inhibition. Br. J. Dermatol. 176 (2017) 212-215.

[40] F. Gómez-García, J.L. Sanz-Cabanillas, I. Viguera-Guerra, B. Isla-Tejera, A.V. Nieto, J. Ruano, Scoping review on use of drugs targeting interleukin 1 pathway in DIRA and DITRA. Dermatol. Ther. (Heidelb). 8 (2018) 539-556.

[41] A. Arakawa, S. Vollmer, P. Besgen, A. Galinski, B. Summer, Y. Kawakami, et al., Unopposed IL-36 activity promotes clonal CD4+ T-cell responses with IL-17A production in generalized pustular psoriasis. J. Invest. Dermatol. 138 (2018) 1338-1347.

[42] S.K. Mahil, M. Catapano, P. Di Meglio, N. Dand, H. Ahlfors, I.M. Carr, et al., An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci. Transl. Med. 9(411) (2017) eaan2514.

[43] H. Bachelez, S.E. Choon, S. Marrakchi, A.D. Burden, T.F. Tsai, A. Morita, et al., Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N. Engl. J. Med. 380 (2019) 981-983.

[44] S.E. Choon, M.G. Lebwohl, S. Marrakchi, A.D. Burden, T.F. Tsai, A. Morita, et al., Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo- controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ. Open. 11 (2021) e043666.

[45] U. Mrowietz, A.D. Burden, A. Pinter, K. Reich, K. Schäkel, P. Baum, et al., Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol. Ther. (Heidelb). 11 (2021) 571-585.

[46] M. Misiak-Galazka, J. Zozula, L. Rudnicka, Palmoplantar pustulosis: Recent advances in etiopathogenesis and emerging treatments. Am. J. Clin. Dermatol. 21 (2020) 355-370.

[47] H. Iznardo, L. Puig. Exploring the role of IL-36 cytokines as a new target in psoriatic disease. Int. J. Mol. Sci. 22 (2021) 4344.

[48] V. Todorović, Z. Su, C.B. Putman, S.J. Kakavas, K.M. Salte, H.A. McDonald, et al., Small molecule IL-36γ antagonist as a novel therapeutic approach for plaque psoriasis. Sci. Rep. 9 (2019) 9089.

[49] L. Skov, F.J. Beurskens, C.O. Zachariae, S. Reitamo, J. Teeling, D. Satijn, et al., IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J. Immunol. 181 (2008) 669-679.

[50] J.J. Campbell, K. Ebsworth, L.S. Ertl, J.P. McMahon, Y. Wang, S. Yau, et al., Efficacy of chemokine receptor inhibition in treating IL-36α-induced psoriasiform inflammation. J. Immunol. 202 (2019) 1687-1692.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る